What the FDA labels say about taking them together
Itraconazole and solifenacin
Itraconazole's FDA label of July 13, 2026 names solifenacin in its boxed warning section; the solifenacin label PlainMeds reads does not name itraconazole. The itraconazole label: “Concomitant drug dose reduction may be necessary Solifenacin Patients with severe renal or moderate to severe hepatic impairment:”
Check it at the source: the itraconazole FDA label on DailyMed (effective July 13, 2026, Janssen Pharmaceuticals, Inc.); the solifenacin FDA label on DailyMed (effective February 4, 2026, Bostal LLC).
What does the itraconazole label say about solifenacin?
Itraconazole label, boxed warningCoadministration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment.
Itraconazole label, contraindicationsIn addition, coadministration with colchicine, fesoterodine, and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (See PRECAUTIONS:
Itraconazole label, drug interactionsSolifenacin Patients with severe renal or moderate to severe hepatic impairment: Contraindicated during and 2 weeks after SPORANOX ® treatment.
Tolsura label (Mayne Pharma Commercial LLC, April 23, 2025), boxed warningDrug Interactions Co-administration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with TOLSURA because plasma concentrations of such drugs are increased. ( 4.1 , 5.5 , 7.1 ) Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment. ( 4.1 , 7.1 ) Co-administration with eliglustat is contraindicated in poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. …
Tolsura label (Mayne Pharma Commercial LLC, April 23, 2025), drug interactionsConcomitant drug dose reduction may be necessary Solifenacin Patients with severe renal or moderate to severe hepatic impairment:
Source: FDA drug label (Tolsura, NDA208901), Mayne Pharma Commercial LLC, effective April 23, 2025 (SPL set 306352d1-9d5a-49ad-b72d-893b99546861), via openFDA
Source: FDA drug label (SPORANOX), Janssen Pharmaceuticals, Inc., effective July 13, 2026 (SPL set a4d555fa-787c-40fb-bb7d-b0d4f7318fd0), via openFDA; the full label on DailyMed
What does the solifenacin label say about itraconazole?
Solifenacin's label (effective February 4, 2026) does not name itraconazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Solifenacin Succinate), Bostal LLC, effective February 4, 2026 (SPL set d155c739-6870-4938-ba91-8c1b4b90afe4), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Itraconazole | Solifenacin | |
|---|---|---|
| Labeled for | Fungal infections | Overactive bladder |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.910 per capsule 100 mg capsule | $0.162 per tablet 10 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once